We’re pleased to welcome Dr Samuel Coe to the team at Hypha as Business Development Manager. Samuel is a medicinal chemist by training having previously worked in the pharma space for Vertex, Charnwood Molecular and Evotec.
Frank will be giving a talk at the EFMC-ISMC 2021 meeting on “Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using PolyCYPs Enzymes”
We’re proud of our team for the recent successful delivery of a client project using Hypha’s One-Stop Metabolite Shop approach. Metabolites of two drug substances were provided, using microbial biotransformation for one drug compound and late-stage chemical synthesis for the other.
We always really appreciate receiving feedback from a client. This time we celebrate project success for Alkermes for whom we used our PolarExplorer platform to deliver novel hydroxylated derivatives of some of their lead compounds. PolarExplorer uses Hypha’s PolyCYPs enzymes to create multiple hydroxylated derivatives of drugs in parallel.
Project Manager and Head of Chemistry Richard Phipps, together with Hypha scientists Renia Gemmell, Chloe Herring and Chris Drake have received great feedback for the successful completion of a challenging metabolite project for a US pharma client. The project involved multiple disciplines of microbial biotransformation, purification and structure elucidation.
We were delighted to welcome some new recruits to the Hypha family this October. Chloe Herring and John Boyle join the Chemistry team and Charlotte Woods joins the Microbiology team.
Hypha’s paper in ACS Medicinal Chemistry Letters on “Biotransformation: Impact and Application of Metabolism in Drug Discovery” was published in August 2020.
Hypha were honoured to be asked to contribute a chapter on “Metabolite Generation and Metabolite Characterization by NMR” in the book just published on “Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters”, edited by Shuguang Ma and Swapan Chowdhury.
Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant enzymes of all five forms of human FMOs have been cloned into E.coli to provide a mechanism to access scalable quantities of FMO derived metabolites.
Stay up to date with the latest news from Hypha Discovery
Sign up for our Newsletter to receive interesting updates and scientific case studies about Hypha’s metabolite generation capabilities and lead optimization solutions
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.